Abstract: This document relates to methods and materials for treating bone loss. For example, compositions containing 4-aminopy-ridine (4-AP) and/or one or more derivatives of 4-AP can be administered (e.g., systemically administered) to a mammal having bone loss to treat the mammal.

Abstract: This document provides methods and materials for treating hair loss. For example, compositions containing 4-aminopyridine (4-AP) and/or one or more derivatives of 4-AP can be administered to a mammal having hair loss to treat the hair loss (e.g., to promote hair growth). Further more, a method for increasing hair regeneration, wherein said method comprises administering a composition comprising 4-AP or one or more derivatives of 4-AP to a mammal identified as being in need of increased hair regeneration.

Abstract: This document relates to methods and materials for using 4-aminopyridine (4-AP) and/or one or more derivatives of 4-AP. For example, a composition containing 4-AP and/or one or more derivatives of 4-AP can be administered (e.g., orally administered) to a mammal to increase a level of bone morphogenetic protein 2 (BMP-2) polypeptides within the mammal. For example, a composition containing 4-AP and/or one or more derivatives of 4-AP can be administered (e.g., orally administered) to a mammal having bone loss to increase the level of BMP-2 within the mammal, thereby treating the mammal's bone loss.

Abstract: This document relates to methods and materials for treating burns. For example, compositions containing 4-aminopyridine (4-AP) and/or one or more derivatives of 4-AP can be administered (e.g., systemically administered) to a mammal having one o more burns to treat the burn(s) (e.g., to promote burn wound healing).

Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.

Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.

Abstract: This document relates to methods and materials for treating nerve injuries. For example, thermoresponsive compositions containing 4-aminopyridine (4-AP) and/or one or more derivatives of 4-AP as well as methods for using such thermoresponsive compositions as a delivery system for 4-AP and/or one or more derivatives of 4-AP (e.g., to treat nerve injury) are provided. This document also provides methods and materials for treating a wound (e.g., a skin wound). For example, compositions containing 4-AP and/or one or more derivatives of 4-AP can be administered (e.g., systemically administered) to a mammal having a wound (e.g., a skin wound) to treat the wound (e.g., to promote wound healing).

Abstract: This document relates to compositions containing one or more erythropoietin (EPO) polypeptides. For example, this document provides thermoresponsive compositions containing one or more EPO polypeptides and methods for using such thermoresponsive compositions as a delivery system to deliver one or more EPO polypeptides to desired tissue (e.g., to treat a nerve injury and/or a wound). In some cases, thermoresponsive compositions containing one or more EPO polypeptides can be administered (e.g., locally administered) to a mammal having a nerve injury to treat the nerve injury (e.g., to promote wound healing). In some cases, thermoresponsive compositions containing one or more EPO polypeptides can be administered (e.g., locally administered) to a mammal having a wound to treat the wound (e.g., to promote wound healing).

Abstract: This invention relates to treating gastrointestinal dysfunction with erythropoietin (EPO) or its analog.

Abstract: This invention relates to treating gastrointestinal dysfunction with erythropoietin (EPO) or its analog.

Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.

Abstract: This invention relates to treating gastrointestinal dysfunction with erythropoietin (EPO) or its analog.

Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.

Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.

Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.